Literature DB >> 31337231

Association of APOL1 Risk Alleles With Cardiovascular Disease in Blacks in the Million Veteran Program.

Alexander G Bick1,2,3, Elvis Akwo4,5, Cassianne Robinson-Cohen4,5, Kyung Lee6, Julie Lynch6,7,8, Themistocles L Assimes9,10, Scott DuVall8, Todd Edwards4,5, Huaying Fang9,10, S Matthew Freiberg4,5, Ayush Giri4,5, Jennifer E Huffman1, Jie Huang1, Leland Hull1,6, Rachel L Kember11,12, Derek Klarin1,2,3, Jennifer S Lee9,10, Michael Levin11,12, Donald R Miller6,13, Pradeep Natarajan2,3, Danish Saleheen11,12, Qing Shao6, Yan V Sun14,15, Hua Tang9,10, Otis Wilson4, Kyong-Mi Chang11,12, Kelly Cho1, John Concato16, J Michael Gaziano1,17, Sekar Kathiresan2,3,17, Christopher J O'Donnell1,17, Daniel J Rader11, Philip S Tsao9,10, Peter W Wilson14,15, Adriana M Hung4,5, Scott M Damrauer11,12.   

Abstract

BACKGROUND: Approximately 13% of black individuals carry 2 copies of the apolipoprotein L1 (APOL1) risk alleles G1 or G2, which are associated with 1.5- to 2.5-fold increased risk of chronic kidney disease. There have been conflicting reports as to whether an association exists between APOL1 risk alleles and cardiovascular disease (CVD) that is independent of the effects of APOL1 on kidney disease. We sought to test the association of APOL1 G1/G2 alleles with coronary artery disease, peripheral artery disease, and stroke among black individuals in the Million Veteran Program.
METHODS: We performed a time-to-event analysis of retrospective electronic health record data using Cox proportional hazard and competing-risks Fine and Gray subdistribution hazard models. The primary exposure was APOL1 risk allele status. The primary outcome was incident coronary artery disease among individuals without chronic kidney disease during the 12.5-year follow-up period. We separately analyzed the cross-sectional association of APOL1 risk allele status with lipid traits and 115 cardiovascular diseases using phenome-wide association.
RESULTS: Among 30 903 black Million Veteran Program participants, 3941 (13%) carried the 2 APOL1 risk allele high-risk genotype. Individuals with normal kidney function at baseline with 2 risk alleles had slightly higher risk of developing coronary artery disease compared with those with no risk alleles (hazard ratio, 1.11 [95% CI, 1.01-1.21]; P=0.039). Similarly, modest associations were identified with incident stroke (hazard ratio, 1.20 [95% CI, 1.05-1.36; P=0.007) and peripheral artery disease (hazard ratio, 1.15 [95% CI, 1.01-1.29l; P=0.031). When both cardiovascular and renal outcomes were modeled, APOL1 was strongly associated with incident renal disease, whereas no significant association with the CVD end points could be detected. Cardiovascular phenome-wide association analyses did not identify additional significant associations with CVD subsets.
CONCLUSIONS: APOL1 risk variants display a modest association with CVD, and this association is likely mediated by the known APOL1 association with chronic kidney disease.

Entities:  

Keywords:  apolipoprotein L1; cardiovascular diseases; genetics; renal insufficiency, chronic

Year:  2019        PMID: 31337231      PMCID: PMC6754626          DOI: 10.1161/CIRCULATIONAHA.118.036589

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  31 in total

1.  Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors.

Authors:  Michelle E Tarver-Carr; Neil R Powe; Mark S Eberhardt; Thomas A LaVeist; Raynard S Kington; Josef Coresh; Frederick L Brancati
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

2.  Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies.

Authors:  Daniel E Weiner; Hocine Tighiouart; Manish G Amin; Paul C Stark; Bonnie MacLeod; John L Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak
Journal:  J Am Soc Nephrol       Date:  2004-05       Impact factor: 10.121

3.  Population-based risk assessment of APOL1 on renal disease.

Authors:  David J Friedman; Julia Kozlitina; Giulio Genovese; Prachi Jog; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

4.  Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions.

Authors:  Andrew S Levey; Lesley A Stevens
Journal:  Am J Kidney Dis       Date:  2010-04       Impact factor: 8.860

5.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Authors:  Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

6.  Validating administrative data in stroke research.

Authors:  David L Tirschwell; W T Longstreth
Journal:  Stroke       Date:  2002-10       Impact factor: 7.914

7.  KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.

Authors:  Alan S Kliger; Robert N Foley; David S Goldfarb; Stuart L Goldstein; Kirsten Johansen; Ajay Singh; Lynda Szczech
Journal:  Am J Kidney Dis       Date:  2013-07-25       Impact factor: 8.860

8.  Association of race and sex with risk of incident acute coronary heart disease events.

Authors:  Monika M Safford; Todd M Brown; Paul M Muntner; Raegan W Durant; Stephen Glasser; Jewell H Halanych; James M Shikany; Ronald J Prineas; Tandaw Samdarshi; Vera A Bittner; Cora E Lewis; Christopher Gamboa; Mary Cushman; Virginia Howard; George Howard
Journal:  JAMA       Date:  2012-11-07       Impact factor: 56.272

9.  Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data.

Authors:  Joshua C Denny; Lisa Bastarache; Marylyn D Ritchie; Robert J Carroll; Raquel Zink; Jonathan D Mosley; Julie R Field; Jill M Pulley; Andrea H Ramirez; Erica Bowton; Melissa A Basford; David S Carrell; Peggy L Peissig; Abel N Kho; Jennifer A Pacheco; Luke V Rasmussen; David R Crosslin; Paul K Crane; Jyotishman Pathak; Suzette J Bielinski; Sarah A Pendergrass; Hua Xu; Lucia A Hindorff; Rongling Li; Teri A Manolio; Christopher G Chute; Rex L Chisholm; Eric B Larson; Gail P Jarvik; Murray H Brilliant; Catherine A McCarty; Iftikhar J Kullo; Jonathan L Haines; Dana C Crawford; Daniel R Masys; Dan M Roden
Journal:  Nat Biotechnol       Date:  2013-12       Impact factor: 54.908

10.  Discovery and refinement of loci associated with lipid levels.

Authors:  Cristen J Willer; Ellen M Schmidt; Sebanti Sengupta; Michael Boehnke; Panos Deloukas; Sekar Kathiresan; Karen L Mohlke; Erik Ingelsson; Gonçalo R Abecasis; Gina M Peloso; Stefan Gustafsson; Stavroula Kanoni; Andrea Ganna; Jin Chen; Martin L Buchkovich; Samia Mora; Jacques S Beckmann; Jennifer L Bragg-Gresham; Hsing-Yi Chang; Ayşe Demirkan; Heleen M Den Hertog; Ron Do; Louise A Donnelly; Georg B Ehret; Tõnu Esko; Mary F Feitosa; Teresa Ferreira; Krista Fischer; Pierre Fontanillas; Ross M Fraser; Daniel F Freitag; Deepti Gurdasani; Kauko Heikkilä; Elina Hyppönen; Aaron Isaacs; Anne U Jackson; Åsa Johansson; Toby Johnson; Marika Kaakinen; Johannes Kettunen; Marcus E Kleber; Xiaohui Li; Jian'an Luan; Leo-Pekka Lyytikäinen; Patrik K E Magnusson; Massimo Mangino; Evelin Mihailov; May E Montasser; Martina Müller-Nurasyid; Ilja M Nolte; Jeffrey R O'Connell; Cameron D Palmer; Markus Perola; Ann-Kristin Petersen; Serena Sanna; Richa Saxena; Susan K Service; Sonia Shah; Dmitry Shungin; Carlo Sidore; Ci Song; Rona J Strawbridge; Ida Surakka; Toshiko Tanaka; Tanya M Teslovich; Gudmar Thorleifsson; Evita G Van den Herik; Benjamin F Voight; Kelly A Volcik; Lindsay L Waite; Andrew Wong; Ying Wu; Weihua Zhang; Devin Absher; Gershim Asiki; Inês Barroso; Latonya F Been; Jennifer L Bolton; Lori L Bonnycastle; Paolo Brambilla; Mary S Burnett; Giancarlo Cesana; Maria Dimitriou; Alex S F Doney; Angela Döring; Paul Elliott; Stephen E Epstein; Gudmundur Ingi Eyjolfsson; Bruna Gigante; Mark O Goodarzi; Harald Grallert; Martha L Gravito; Christopher J Groves; Göran Hallmans; Anna-Liisa Hartikainen; Caroline Hayward; Dena Hernandez; Andrew A Hicks; Hilma Holm; Yi-Jen Hung; Thomas Illig; Michelle R Jones; Pontiano Kaleebu; John J P Kastelein; Kay-Tee Khaw; Eric Kim; Norman Klopp; Pirjo Komulainen; Meena Kumari; Claudia Langenberg; Terho Lehtimäki; Shih-Yi Lin; Jaana Lindström; Ruth J F Loos; François Mach; Wendy L McArdle; Christa Meisinger; Braxton D Mitchell; Gabrielle Müller; Ramaiah Nagaraja; Narisu Narisu; Tuomo V M Nieminen; Rebecca N Nsubuga; Isleifur Olafsson; Ken K Ong; Aarno Palotie; Theodore Papamarkou; Cristina Pomilla; Anneli Pouta; Daniel J Rader; Muredach P Reilly; Paul M Ridker; Fernando Rivadeneira; Igor Rudan; Aimo Ruokonen; Nilesh Samani; Hubert Scharnagl; Janet Seeley; Kaisa Silander; Alena Stančáková; Kathleen Stirrups; Amy J Swift; Laurence Tiret; Andre G Uitterlinden; L Joost van Pelt; Sailaja Vedantam; Nicholas Wainwright; Cisca Wijmenga; Sarah H Wild; Gonneke Willemsen; Tom Wilsgaard; James F Wilson; Elizabeth H Young; Jing Hua Zhao; Linda S Adair; Dominique Arveiler; Themistocles L Assimes; Stefania Bandinelli; Franklyn Bennett; Murielle Bochud; Bernhard O Boehm; Dorret I Boomsma; Ingrid B Borecki; Stefan R Bornstein; Pascal Bovet; Michel Burnier; Harry Campbell; Aravinda Chakravarti; John C Chambers; Yii-Der Ida Chen; Francis S Collins; Richard S Cooper; John Danesh; George Dedoussis; Ulf de Faire; Alan B Feranil; Jean Ferrières; Luigi Ferrucci; Nelson B Freimer; Christian Gieger; Leif C Groop; Vilmundur Gudnason; Ulf Gyllensten; Anders Hamsten; Tamara B Harris; Aroon Hingorani; Joel N Hirschhorn; Albert Hofman; G Kees Hovingh; Chao Agnes Hsiung; Steve E Humphries; Steven C Hunt; Kristian Hveem; Carlos Iribarren; Marjo-Riitta Järvelin; Antti Jula; Mika Kähönen; Jaakko Kaprio; Antero Kesäniemi; Mika Kivimaki; Jaspal S Kooner; Peter J Koudstaal; Ronald M Krauss; Diana Kuh; Johanna Kuusisto; Kirsten O Kyvik; Markku Laakso; Timo A Lakka; Lars Lind; Cecilia M Lindgren; Nicholas G Martin; Winfried März; Mark I McCarthy; Colin A McKenzie; Pierre Meneton; Andres Metspalu; Leena Moilanen; Andrew D Morris; Patricia B Munroe; Inger Njølstad; Nancy L Pedersen; Chris Power; Peter P Pramstaller; Jackie F Price; Bruce M Psaty; Thomas Quertermous; Rainer Rauramaa; Danish Saleheen; Veikko Salomaa; Dharambir K Sanghera; Jouko Saramies; Peter E H Schwarz; Wayne H-H Sheu; Alan R Shuldiner; Agneta Siegbahn; Tim D Spector; Kari Stefansson; David P Strachan; Bamidele O Tayo; Elena Tremoli; Jaakko Tuomilehto; Matti Uusitupa; Cornelia M van Duijn; Peter Vollenweider; Lars Wallentin; Nicholas J Wareham; John B Whitfield; Bruce H R Wolffenbuttel; Jose M Ordovas; Eric Boerwinkle; Colin N A Palmer; Unnur Thorsteinsdottir; Daniel I Chasman; Jerome I Rotter; Paul W Franks; Samuli Ripatti; L Adrienne Cupples; Manjinder S Sandhu; Stephen S Rich
Journal:  Nat Genet       Date:  2013-10-06       Impact factor: 38.330

View more
  19 in total

1.  Current status and future directions of U.S. genomic nursing health care policy.

Authors:  Emma Kurnat-Thoma; Mei R Fu; Wendy A Henderson; Joachim G Voss; Marilyn J Hammer; Janet K Williams; Kathleen Calzone; Yvette P Conley; Angela Starkweather; Michael T Weaver; S Pamela K Shiao; Bernice Coleman
Journal:  Nurs Outlook       Date:  2021-01-22       Impact factor: 3.250

2.  A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins.

Authors:  Valentin Blanchard; Damien Garçon; Catherine Jaunet; Kevin Chemello; Stéphanie Billon-Crossouard; Audrey Aguesse; Aya Garfa; Gilles Famchon; Amada Torres; Cédric Le May; Matthieu Pichelin; Edith Bigot-Corbel; Gilles Lambert; Bertrand Cariou; Samy Hadjadj; Michel Krempf; Kalyane Bach-Ngohou; Mikaël Croyal
Journal:  J Lipid Res       Date:  2020-05-13       Impact factor: 5.922

3.  APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.

Authors:  Adriana M Hung; Shailja C Shah; Alexander G Bick; Zhihong Yu; Hua-Chang Chen; Christine M Hunt; Frank Wendt; Otis Wilson; Robert A Greevy; Cecilia P Chung; Ayako Suzuki; Yuk-Lam Ho; Elvis Akwo; Renato Polimanti; Jin Zhou; Peter Reaven; Philip S Tsao; J Michael Gaziano; Jennifer E Huffman; Jacob Joseph; Shiuh-Wen Luoh; Sudha Iyengar; Kyong-Mi Chang; Juan P Casas; Michael E Matheny; Christopher J O'Donnell; Kelly Cho; Ran Tao; Katalin Susztak; Cassianne Robinson-Cohen; Sony Tuteja; Edward D Siew
Journal:  JAMA Intern Med       Date:  2022-04-01       Impact factor: 21.873

4.  Apolipoprotein L1 Gene Testing Comes of Age.

Authors:  Barry I Freedman; Chris P Larsen
Journal:  Kidney360       Date:  2020-01-08

Review 5.  Podocytopathies.

Authors:  Jeffrey B Kopp; Hans-Joachim Anders; Katalin Susztak; Manuel A Podestà; Giuseppe Remuzzi; Friedhelm Hildebrandt; Paola Romagnani
Journal:  Nat Rev Dis Primers       Date:  2020-08-13       Impact factor: 52.329

6.  APOL1 Genetic Variants Are Associated With Increased Risk of Coronary Atherosclerotic Plaque Rupture in the Black Population.

Authors:  Anne Cornelissen; Daniela T Fuller; Raquel Fernandez; Xiaoqing Zhao; Robert Kutys; Elizabeth Binns-Roemer; Marco Delsante; Atsushi Sakamoto; Ka Hyun Paek; Yu Sato; Rika Kawakami; Masayuki Mori; Kenji Kawai; Teruhiko Yoshida; Khun Zaw Latt; Clint L Miller; Paul S de Vries; Frank D Kolodgie; Renu Virmani; Myung Kyun Shin; Maarten Hoek; Jurgen Heymann; Jeffrey B Kopp; Avi Z Rosenberg; Harry R Davis; Liang Guo; Aloke V Finn
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-05-27       Impact factor: 10.514

7.  APOL1 at 10 years: progress and next steps.

Authors:  Barry I Freedman; Jeffrey B Kopp; Matthew G Sampson; Katalin Susztak
Journal:  Kidney Int       Date:  2021-03-29       Impact factor: 18.998

8.  Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways.

Authors:  Archna Bajaj; Andrea Ihegword; Chengxiang Qiu; Aeron M Small; Wei-Qi Wei; Lisa Bastarache; QiPing Feng; Rachel L Kember; Marjorie Risman; Roy D Bloom; David L Birtwell; Heather Williams; Christian M Shaffer; Jinbo Chen; Regeneron Genetics Center; Joshua C Denny; Daniel J Rader; C Michael Stein; Scott M Damrauer; Katalin Susztak
Journal:  Kidney Int       Date:  2020-02-17       Impact factor: 10.612

9.  Cooperative Studies Program (CSP) #572: A Study of Serious Mental Illness in Veterans as a Pathway to personalized medicine in Schizophrenia and Bipolar Illness.

Authors:  Philip D Harvey; Tim B Bigdeli; Ayman H Fanous; Yuli Li; Nallakkandi Rajeevan; Frederick Sayward; Krishnan Radhakrishnan; Grant Huang; Mihaela Aslan
Journal:  Pers Med Psychiatry       Date:  2021-07

10.  Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program.

Authors:  Elvis A Akwo; Cassianne Robinson-Cohen; Cecilia P Chung; Shailja C Shah; Nancy J Brown; T Alp Ikizler; Otis D Wilson; Bryce X Rowan; Megan M Shuey; Edward D Siew; James M Luther; Ayush Giri; Jacklyn N Hellwege; Digna R Velez Edwards; Christianne L Roumie; Ran Tao; Phil S Tsao; J Michael Gaziano; Peter W F Wilson; Christopher J O'Donnell; Todd L Edwards; Csaba P Kovesdy; Adriana M Hung
Journal:  Hypertension       Date:  2021-06-21       Impact factor: 9.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.